Cite
Bone marrow biopsy superiority over PET/CT in predicting progression-free survival in a homogeneously-treated cohort of diffuse large B-cell lymphoma.
MLA
Chen-Liang, Tzu-Hua, et al. “Bone Marrow Biopsy Superiority over PET/CT in Predicting Progression-Free Survival in a Homogeneously-Treated Cohort of Diffuse Large B-Cell Lymphoma.” Cancer Medicine, vol. 6, no. 11, Nov. 2017, pp. 2507–14. EBSCOhost, https://doi.org/10.1002/cam4.1205.
APA
Chen-Liang, T.-H., Martín-Santos, T., Jerez, A., Rodríguez-García, G., Senent, L., Martínez-Millán, C., Muiña, B., Orero, M., Teruel, A., Martín, A., Gómez-Espuch, J., Kennedy, K., Benet, C., Raya, J. M., Fernández-González, M., de la Cruz, F., Guinot, M., Villegas, C., Ballester, I., … Ortuño, F. J. (2017). Bone marrow biopsy superiority over PET/CT in predicting progression-free survival in a homogeneously-treated cohort of diffuse large B-cell lymphoma. Cancer Medicine, 6(11), 2507–2514. https://doi.org/10.1002/cam4.1205
Chicago
Chen-Liang, Tzu-Hua, Taida Martín-Santos, Andrés Jerez, Guillermo Rodríguez-García, Leonor Senent, Cristina Martínez-Millán, Begoña Muiña, et al. 2017. “Bone Marrow Biopsy Superiority over PET/CT in Predicting Progression-Free Survival in a Homogeneously-Treated Cohort of Diffuse Large B-Cell Lymphoma.” Cancer Medicine 6 (11): 2507–14. doi:10.1002/cam4.1205.